Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers

Pharmaceutical Research

Volumn 19, Issue 11, 2002, Pages 1704-1712

  Rouquayrol, Marielle ^a   Gaucher, Bérangère ^a   Roche, Dominique ^a   Greiner, Jacques ^a   Vierling, Pierre ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Amino acid; Antiproteases; Glucose; Intestinal transport; P glycoprotein; Polyethylene glycol

Indexed keywords

DRUG CARRIER; GLUCOSE; GLYCOPROTEIN P; INDINAVIR; INDINAVIR GLUCOSE; INDINAVIR MACROGOL 2000; INDINAVIR TYROSINE ESTER; INDINAVIR VALINE ESTER; MACROGOL; NELFINAVIR; NELFINAVIR GLUCOSE; NELFINAVIR TYROSINE ESTER; PRODRUG; PROTEINASE INHIBITOR; SAQUINAVIR; SAQUINAVIR GLUCOSE; SAQUINAVIR LEUCINE ESTER; SAQUINAVIR MACROGOL 2000; SAQUINAVIR PHENYLALANINE ESTER; SAQUINAVIR TYROSINE ESTER; SAQUINAVIR VALINE ESTER; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL GROWTH; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; CONTROLLED STUDY; DIFFUSION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG STRUCTURE; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INTESTINE ABSORPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; EPITHELIAL CELLS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; NELFINAVIR; PRODRUGS; SAQUINAVIR;

EID: 0036845777     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020913631309     Document Type: Article

References (20)

1. R. J. Sawchuk and Z. Yang. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv. Drug Deliv. Rev. 39:5-31 (1999).
2. J. Blankson, D. Persaud, and R. F. Siliciano. Latent reservoirs for HIV-1. Curr. Opin. Infect. Dis. 12:5-11 (1999).
3. R. M. W. Hoetelmans, P. L. Meenhorst, J. W. Mulder, D. M. Burger, C. H. W. Koks, and J. H. Beijnen. Clinical pharmacology of HIV protease inhibitors: Focus on saquinavir, indinavir, and ritonavir. Pharm. World Sci. 19:159-175 (1997).
4. K. Z. Rana and M. N. Dudley. Human immunodeficiency virus protease inhibitors. Pharmacotherapy 19:35-59 (1999).
5. W. Wang, J. Jiang, C. E. Ballard, and B. Wang, Prodrug approaches to the improved delivery of peptide drugs. Curr. Pharm. Design 5:265-287 (1999).
6. I. Tamai and A. Tsuji. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89:1371-1388 (2000).
7. S. M. Foroutan and D. G. Watson. Synthesis and characterisation of polyethylene glycol conjugates of hydrocortisone as potential prodrugs for ocular steroid delivery. Int. J. Pharm. 157:103-111 (1997).
8. A. Farèse-Di Giorgio, M. Rouquayrol, J. Greiner, A.-M. Aubertin, P. Vierling, and R. Guedj. Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir. Antivir. Chem. Chemother. 11:97-110 (2000).
9. M. Rouquayrol, B. Gaucher, J. Greiner, A.-M. Aubertin, P. Vierling, and R. Guedj. Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir. Carbohydr. Res. 336:161-180 (2001).
10. P. Artursson. Ceil cultures as models for drug absorption across the intestinal mucosa. Crit. Rev. Ther. Drug Carrier Syst. 8:305-330 (1991).
11. L.-S. Gan, C. Eads, T. Niederer, A. Bridgers, S. Yanni, P.-H. Hsyu, F. J. Pritchard, and D. Thakker. Use of Caco-2 cells as an in vitro intestinal absorption and metabolism model. Drug Develop. Ind. Pharm. 20:615-631 (1994).
12. P. Annaert, G. Gosselin, A. Pompon, S. Benzaria, G. Valette, J. L. Imbach, L. Naesens, S. Hatse, E. De Clercq, G. Van den Mooter, R. Kinget, and P. Augustijns. Comparison of the disposition of ester prodrugs of the antiviral agent 9-(2-phosphonyl-methoxyethyl)adenine [PMEA] in Caco-2 monolayers. Pharm. Res. 15:239-245 (1998).
13. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J.-J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
14. B. J. Aungst, N. H. Nguyen, J. P. Bulgarelli, and K. Oates-Lenz. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm. Res. 17:1175-1180 (2000).
15. M. L. West and D. P. Fairlie. Targeting HIV-1 protease: A test of drug-design methodologies. TiPS 16:67-75 (1995).
16. P. Augustijns, P. Annaert, P. Heylen, G. Van den Mooter, and R. Kinget. Drug absorption studies of prodrug esters using the Caco-2 model: Evaluation of ester hydrolysis and transepithelial transport. Int. J. Pharm. 166:45-53 (1998).
17. K. I. Hosoya, K. J. Kim, and V. H. Lee. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res. 13:885-890 (1996).
18. W. H. Oldendorf. Stereospecificity of blood-brain barrier permeability to amino acids. Am. J. Physiol. 224:967-969 (1973).
19. I. Walker, D. Nicholls, W. J. Irwin, and S. Freeman. Drug delivery via active transport at the blood-brain barrier: Affinity of a prodrug of phosphonoformate for the large amino acid transporter. Int. J. Pharm. 104:157-167 (1994).
20. E. Walter, S. Janich, B. J. Roessler, J. M. Hilfinger, and G. L. Amidon. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: In vitro-in vivo correlation with permeability data from rats and humans. J. Pharm. Sci. 85:1070-1076 (1996).